Published in AIDS on May 23, 2003
Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol (2008) 1.30
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol (2005) 1.28
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol (2006) 1.15
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (2004) 1.09
Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol (2008) 1.04
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2004) 0.97
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother (2005) 0.96
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther (2007) 0.95
Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 0.93
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol (2005) 0.92
Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics (2011) 0.91
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol (2005) 0.91
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol (2007) 0.90
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol (2015) 0.88
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial. Fundam Clin Pharmacol (2009) 0.87
Monitoring therapy. Br J Clin Pharmacol (2005) 0.85
Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. Can J Hosp Pharm (2012) 0.85
Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother (2006) 0.85
Individualization of antiretroviral therapy. Pharmgenomics Pers Med (2011) 0.83
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. Ther Drug Monit (2011) 0.81
Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother (2012) 0.80
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother (2008) 0.79
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. BMC Infect Dis (2013) 0.79
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm (2009) 0.79
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials (2011) 0.78
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol (2006) 0.76
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Whither or wither microbicides? Science (2008) 2.17
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Chronic renal failure among HIV-1-infected patients. AIDS (2007) 2.07
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology (2010) 1.98
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS (2016) 1.97
Continuous antiretroviral therapy decreases bone mineral density. AIDS (2009) 1.96
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol (2005) 1.75
HIV-1 infection and cognitive impairment in the cART era: a review. AIDS (2011) 1.72
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med (2014) 1.69
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol (2006) 1.66
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis (2005) 1.62
Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis (2007) 1.61
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther (2002) 1.61
The restoration potential of the Mesopotamian marshes of Iraq. Science (2005) 1.60
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis (2014) 1.59
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 1.58
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis (2010) 1.56
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
Effects of antiretroviral therapy on semen quality. AIDS (2008) 1.54
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med (2012) 1.54
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis (2005) 1.52
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother (2013) 1.44
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. Tuberculosis (Edinb) (2014) 1.43
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
One-pot synthesis of highly luminescent InP/ZnS nanocrystals without precursor injection. J Am Chem Soc (2008) 1.39
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother (2011) 1.36
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Extrapulmonary tuberculosis by nationality, The Netherlands, 1993-2001. Emerg Infect Dis (2006) 1.34
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (2011) 1.31
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill (2015) 1.29
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit (2003) 1.28
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS (2005) 1.28
Prospects of nanoscience with nanocrystals. ACS Nano (2015) 1.27
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS (2009) 1.27
Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One (2008) 1.27
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis (2011) 1.22